Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures.
Luisa WeissJohn KeaneyPaulina B SzklannaTadhg PrendivilleWido UhrigKieran WynneSarah KelliherKarl EwinsShane P ComerKarl EganEllen O'RourkeEric MoranGeorgi PetrovAshish PatelÁine LennonAlfonso BlancoBarry KevaneSean MurphyFionnuala Ní ÁinlePatricia B MaguirePublished in: Journal of thrombosis and haemostasis : JTH (2021)
Collectively, these data demonstrate that NVAF patients anticoagulated with rivaroxaban (compared with warfarin) exhibit both a reduced pro-inflammatory state and evidence of reduced endothelial activation. These findings are of translational relevance toward characterizing the anti-inflammatory and cardiovascular-protective mechanisms associated with rivaroxaban therapy.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- end stage renal disease
- direct oral anticoagulants
- oral anticoagulants
- ejection fraction
- chronic kidney disease
- newly diagnosed
- left atrial
- catheter ablation
- pulmonary embolism
- heart failure
- left atrial appendage
- peritoneal dialysis
- gene expression
- percutaneous coronary intervention
- mesenchymal stem cells
- genome wide
- binding protein
- bone marrow
- electronic health record
- data analysis